EVP-ABD: AN IMPROVED LIVER SPECIFIC AGENT FOR MRI

肝病仍然是准确鉴别诊断的主要挑战。 肝脏中常见几种不同类型的病变。 肝脏是许多恶性肿瘤转移的主要病灶。 通常，良性和恶性病变共存。 明确区分每种病变类型对于最佳治疗计划和随访至关重要。 尽管技术不断进步，但仍有大量病变被漏诊或误诊。 仍然明显需要使快速发展的诊断技术的能力最大化的改进的成像剂。Eagle Vision Pharmaceutical Corp.（EVPC）正在开发一种药物，以满足改善肝脏和腹部疾病鉴别诊断的未满足需求。EVP-ABD是一种基于锰（Mn）的磁共振成像（MRI）造影剂，旨在被肝细胞摄取并在胆汁中消除。 EVP-ABD独特的磁性和动力学特性预计将为血管和肝细胞提供高水平的增强。 这将克服目前MRI用于肝脏成像的局限性，并提供更好的信息来区分各种恶性和良性病变。该I期计划将定义EVP-ABD用于肝脏成像的基本效用，确认其作为改进剂的可行性。拟议的商业应用：这项研究的长期目标是在美国和其他地方注册EVP-ABD作为肝脏和腹部MRI的造影剂。 通过将ECF试剂的血管增强和动力学与肝细胞试剂的增强的组织和病变特异性模式相结合，EVP- ABD应该提供比当前替代方案更具成本效益、侵入性更小和更准确的诊断。

Liver disease remains a major challenge for accurate differential diagnosis. Several different types of lesions are commonly found in the liver. The liver is a prime focus for metastatic extension of numerous malignancies. Often, both benign and malignant lesions co-exist. It is critical for optimal treatment planning and follow-up to clearly differentiate each lesion type. Despite advances in technology, a large number of lesions are missed or incorrectly diagnosed. There remains a clear need for improved imaging agents that maximize the capabilities of the rapidly evolving diagnostic technologies. Eagle Vision Pharmaceutical Corp. (EVPC) is developing an agent that addresses unmet needs for the improved differential diagnosis for diseases of the liver and abdomen. EVP-ABD is a manganese (Mn) based magnetic resonance imaging (MRI) contrast agent designed to be taken up by hepatocytes and eliminated in the bile. The unique magnetic and kinetic properties of EVP-ABD are anticipated to provide high levels of enhancement for both the blood vessels and liver cells. This should overcome current limitations to the use of MRI for liver imaging and provide better information to discriminate between various malignant and benign lesions. This Phase I program will define the fundamental utility of EVP-ABD for liver imaging, confirming its feasibility as an improved agent. PROPOSED COMMERCIAL APPLICATIONS: The long-term goal of this research is to register EVP-ABD in the U.S. and elsewhere as a contrast agent for liver and abdominal MRI. By combining the vascular enhancement and kinetics of ECF agents with the tissue and lesion specific patterns of enhancement of hepatocellular agents, EVP- ABD should provide a more cost-effective, less invasive and more accurate diagnosis than current alternatives.